FibroGen (FGEN)
(Delayed Data from NSDQ)
$0.36 USD
+0.02 (6.02%)
Updated Oct 11, 2024 04:00 PM ET
After-Market: $0.36 0.00 (0.76%) 7:58 PM ET
3-Hold of 5 3
D Value D Growth A Momentum C VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$0.36 USD
+0.02 (6.02%)
Updated Oct 11, 2024 04:00 PM ET
After-Market: $0.36 0.00 (0.76%) 7:58 PM ET
3-Hold of 5 3
D Value D Growth A Momentum C VGM
Zacks News
FibroGen (FGEN) Pamrevlumab Fails DMD Study, Stock Down 8%
by Zacks Equity Research
FibroGen???s (FGEN) phase III study, evaluating pamrevlumab as a combination therapy in certain DMD patients, fails to meet its primary endpoint.
FibroGen (FGEN) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
FibroGen (FGEN) delivered earnings and revenue surprises of -6.58% and 17.02%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
ProPhase Labs, Inc. (PRPH) Surges 8.5%: Is This an Indication of Further Gains?
by Zacks Equity Research
ProPhase Labs, Inc. (PRPH) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
Alaunos (TCRT) to Report Q4 Earnings: What's in the Cards?
by Zacks Equity Research
Alaunos Therapeutics (TCRT) is expected to provide an update on its pipeline candidates, Library TCR-T cell therapy and mbIL-15 TCR-T cell therapy, in its fourth-quarter earnings.
FibroGen (FGEN) Reports Q4 Loss, Tops Revenue Estimates
by Zacks Equity Research
FibroGen (FGEN) delivered earnings and revenue surprises of 26.32% and 43.89%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
Should You Buy FibroGen (FGEN) Ahead of Earnings?
by Zacks Equity Research
FibroGen (FGEN) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
4 Drug, Biotech Stocks Poised to Beat Q4 Earnings Estimates
by Ekta Bagri
We look at a few drug/biotech companies, TBPH, FGEN, AUPH, CYTK, which are poised to beat on earnings in the fourth quarter.
Analysts Estimate ImmunoGen (IMGN) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
ImmunoGen (IMGN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
FibroGen (FGEN) Expected to Beat Earnings Estimates: What to Know Ahead of Q4 Release
by Zacks Equity Research
FibroGen (FGEN) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Ardelyx Inc. (ARDX) to Report Q4 Earnings: What's in Store?
by Zacks Equity Research
Ardelyx (ARDX) is expected to report better-than-expected sales growth of its only marketed product, Ibsrela (tenapanor) and provide an update on the NDA resubmission timeline for Xphozah, tenapanor.
Zoetis (ZTS) to Report Q4 Earnings: What's in the Cards?
by Zacks Equity Research
Higher sales of Zoetis' (ZTS) key drugs like Apoquel, Cytopoint, Simparica Trio, Librela and Solensia are expected to have driven sales, partially offset by lower sales of livestock, cattle, poultry and swine products.
GSK's Daprodustat Drug for Anemia Due to CKD Gets FDA Nod
by Zacks Equity Research
GSK announces the FDA approval of daprodustat for the treatment of anemia due to chronic kidney disease (CKD) in adults on dialysis for at least four months.
FibroGen (FGEN) Reports Q3 Loss, Misses Revenue Estimates
by Zacks Equity Research
FibroGen (FGEN) delivered earnings and revenue surprises of -18.07% and 53.74%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
Earnings Preview: FibroGen (FGEN) Q3 Earnings Expected to Decline
by Zacks Equity Research
FibroGen (FGEN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
FibroGen (FGEN) Reports Q2 Loss, Misses Revenue Estimates
by Zacks Equity Research
FibroGen (FGEN) delivered earnings and revenue surprises of 17.02% and 18.57%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
FibroGen (FGEN) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
FibroGen (FGEN) delivered earnings and revenue surprises of 19.05% and 120.72%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
ImmunoGen (IMGN) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
ImmunoGen (IMGN) delivered earnings and revenue surprises of 52.38% and 56.39%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
ChemoCentryx (CCXI) Reports Q1 Loss, Misses Revenue Estimates
by Zacks Equity Research
ChemoCentryx (CCXI) delivered earnings and revenue surprises of -83.33% and 78.77%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
FibroGen (FGEN) Expected to Beat Earnings Estimates: Should You Buy?
by Zacks Equity Research
FibroGen (FGEN) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Molina Healthcare (MOH) Q1 Earnings Beat on Higher Premiums
by Zacks Equity Research
Molina Healthcare (MOH) boosts premium and bottom-line guidance for 2022, reflecting improving business.
Humana (HUM) Q1 Earnings Beat on Solid Healthcare Services
by Zacks Equity Research
Humana (HUM) still has $2 billion remaining under its share repurchase authorization.
FibroGen (FGEN) Reports Q4 Loss, Lags Revenue Estimates
by Zacks Equity Research
FibroGen (FGEN) delivered earnings and revenue surprises of -113.24% and 62.59%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
Aclaris Therapeutics (ACRS) Reports Q4 Loss, Misses Revenue Estimates
by Zacks Equity Research
Aclaris (ACRS) delivered earnings and revenue surprises of -2.78% and 16.98%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
Analysts Estimate FibroGen (FGEN) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
FibroGen (FGEN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
FibroGen (FGEN) Q3 Earnings and Revenues Surpass Estimates
by Zacks Equity Research
FibroGen (FGEN) delivered earnings and revenue surprises of 500.00% and 15.25%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?